Optimize your pharmaceutical portfolio strategy
Our pipeline data, historical metrics, deals and milestone information and forecasts arm you with the data you need to optimize your company's portfolio.
As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.
How we can help
Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Pharma 360
13 May 2022
Join Informa Pharma Intelligence for the “Global Oncology Opportunities” webinar!
In Vivo
02 Mar 2022
Look ahead with our Pharma Outlook 2022 Extract as we discuss what's coming up in the biopharma space.
In Vivo
By Alex Shimmings 05 Jan 2022
2021 may have been dominated by the continuing coronavirus pandemic, but that did not stop industry’s more bread and butter R&D activities. Here, In Vivo takes a look at five of the more notable clinical trial hits of the year.
In Vivo
By Ashley Yeo 28 Dec 2021
At the end of a turbulent year for health care, COVID-19 is still dominating the thoughts of stakeholders, but CMS patent attorneys Jane Hollywood and Rob Stephen are encouraged by the innovation and investment trends that are making it an exciting time to be in the thick of the action.
In Vivo
By Lucie Ellis-Taitt 22 Nov 2021
Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.
In Vivo
By Joanne Shorthouse 17 Nov 2021
Young businesses are getting set to disrupt every inch of the healthcare space with digital twin technology. Outlook spoke to two startups on the brink of a data dawn.
In Vivo
By Ben Comer 14 Oct 2021
Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.
In Vivo
08 Oct 2021
The highly anticipated Outlook 2022 report from Informa Pharma Intelligence is coming soon. Reach the thousands of senior decision makers who eagerly await this pharma industry ranking and review for the year ahead, with sponsorship opportunities that align your brand with our trusted information.
Biomedtracker, Datamonitor Healthcare
23 Sep 2021
Released July 22, 2021. Contains information like likelihood of approval (LOA) ratings and upcoming catalysts that are current as of April 2021.
Biomedtracker, Datamonitor Healthcare
21 Sep 2021
Against a backdrop of unprecedented disruption, the biopharma and medtech industries reached incredible heights for deal-making activity during 2020.
Topic Drug Review Coronavirus
In Vivo
By Ben Comer 07 Sep 2021
Treating opioid addiction successfully requires an individualized approach, and a lot of money. Executives at addiction treatment centers discuss existing barriers in the recovery pathway and the need to destigmatize addiction and mental health disorders.
In Vivo
18 Aug 2021
Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.
In Vivo
By William Masters 16 Aug 2021
Progress in reducing HIV infections has plateaued in the US. But with bipartisan support, federal funding and momentum in drug development there is reason for optimism, says HIV + Hepatitis Policy Institute executive director Carl Schmid.
In Vivo
By Mark Ratner 12 Aug 2021
Brazil has established an accelerated pathway for approval of drugs for ultra-rare diseases, encouraging development activity – but the definition of qualifying drugs is narrow. Expansion to include more treatments could boost clinical trials activity and companies’ overall development presence.
Datamonitor Healthcare, Biomedtracker, Scrip
11 Aug 2021
The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.
Topic Cancer
In Vivo
25 May 2022
In Vivo
25 May 2022
In Vivo
25 May 2022
In Vivo
23 May 2022
In Vivo
23 May 2022
In Vivo
23 May 2022
In Vivo
18 May 2022
In Vivo
11 May 2022
In Vivo
11 May 2022
In Vivo
09 May 2022
In Vivo
09 May 2022
In Vivo
04 May 2022
In Vivo
04 May 2022
In Vivo
04 May 2022
In Vivo
28 Apr 2022
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: